Can-Fite BioPharma (CANF) Consolidated Net Income (2014 - 2023)

Can-Fite BioPharma (CANF) has 10 years of Consolidated Net Income data on file, last reported at -$28.5 million in Q4 2023.

• Quarterly Consolidated Net Income fell 2.89% year-over-year to -$28.5 million in Q4 2023, while the trailing twelve-month figure through Jun 2025 was -$28.5 million (up 13.96% YoY) and the FY2025 annual result came in at -$9.8 million, down 24.72% from the prior year.
• Consolidated Net Income slipped to -$28.5 million in Q4 2023, from -$1.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $1.6 million in Q1 2019 to a low of -$28.5 million in Q4 2023.
• A 5-year average of -$5.5 million and a median of -$2.7 million in 2023 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2019 — Consolidated Net Income tumbled 745.11% — and 2021, when it soared 49.23%.
• Tracing CANF's Consolidated Net Income over 5 years: stood at -$2.1 million in 2019, then sank by 106.85% to -$4.3 million in 2020, then tumbled by 54.28% to -$6.7 million in 2021, then sank by 312.87% to -$27.7 million in 2022, then fell by 2.89% to -$28.5 million in 2023.
• The last three Consolidated Net Income figures came in at -$28.5 million (Q4 2023), -$1.9 million (Q3 2023), and -$2.8 million (Q2 2023), per Business Quant data.